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Abstract
Background: Infection with hepatitis C virus (HCV) is associated with high morbidity and increased mortality but
many patients avoid initiation of treatment or report challenges with treatment completion. The study objective
was to identify motivators and barriers for treatment initiation and completion in a community sample of
HCV-infected patients in the United States.
Methods: Survey methods were employed to identify factors reported by patients as important in their decision to
start or complete HCV treatment. Study participants included 120 HCV-infected individuals: 30 had previously
completed treatment with pegylated interferon/ribavirin (PR), 30 had discontinued PR, 30 were treated with PR at
the time of the survey, and 30 were treatment‐naïve. Telephone interviews occurred between May and August of
2011 and employed a standardized guide. Participants assigned factors a rating from 1 (not at all important) to 5
(extremely important). Trained researchers coded and analyzed interview transcripts.
Results: Of 33 factors, expected health problems from not treating HCV infection was reported as most
encouraging for treatment initiation and completion, while treatment side effects was most discouraging. Sixty-nine
percent of participants reported that the ability to obtain information during treatment on the likelihood of
treatment success (i.e., results of viral load testing) would motivate them to initiate therapy. Median preferred
timing for learning about test results was 5 weeks (range: 1–23 weeks).
Conclusion: Understanding challenges and expectations from patients is important in identifying opportunities for
education to optimize patient adherence to their HCV treatment regimen.
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Background
Hepatitis C is a liver disease resulting from infection with
the hepatitis C virus (HCV); the estimated disease preva-
lence in the United States is 5 million [1]. Acute hepatitis
C occurs within the first six months after exposure to the
HCV, and 75% to 85% of subjects become chronically
infected. Most patients do not exhibit any symptoms (e.g.,
fatigue, fever, loss of appetite, nausea, vomiting, abdominal
pain, joint pain, and jaundice) [2,3]. About 65% of all
HCV-infected patients experience chronic liver damage,
which can eventually lead to serious complications, in-
cluding death [3,4].
Until 2011, the standard of care for patients with geno-
type 1 chronic HCV infection was a dual combination
regimen of pegylated interferon and ribavirin (PR) [5].
Pegylated interferon is injected once weekly and ribavirin
is taken orally twice a day with food. In this patient popu-
lation, the typical duration of therapy was 48 weeks [5-7]
and resulted in a sustained virologic response (SVR) in
40% to 50% of patients [5]. Treatment with PR is associ-
ated with significant side effects, in particular anemia, fa-
tigue, and depressive symptoms.
Two direct-acting antiviral agents (DAA) – telaprevir
and boceprevir – were approved for use in the United
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States and other countries in 2011 for the treatment of
adults with genotype 1 HCV with compensated liver
disease. Treatment with a DAA in combination with PR
has improved SVR rates for treatment naïve patients with
genotype 1 HCV infection to around 60% to 75% [5].
Furthermore, these new treatment regimens have
allowed for shorter duration of therapy (i.e., 24 weeks) in
eligible patients [5]. Increased treatment options with
greater clinical efficacy than PR alone have renewed
interest in understanding patient behavior and decision-
making associated with HCV treatment initiation and
completion. As DAA-based regimens include interferon
and ribavirin, completing treatment remains challenging
for many patients.
Several approaches to understanding the physical, de-
mographic, emotional, and social factors that might mo-
tivate patients to start HCV therapy have been described
in the literature, including those that focus on the struc-
ture of the decision making (e.g., risk-benefit review) [8].
Reasons associated with the decision to initiate treatment
include the following: expectations of treatment effect-
iveness, threat of disease progression, the availability of
care, lack of alcohol dependence, and readiness to stop
using drugs [9,10]. Conversely, studies have shown that
common deterrents to the initiation of HCV treatment
include lack of disease symptoms, anticipated side effects
from treatment, and the presence of comorbid conditions
[11]. To date, many studies have focused on specific
high-risk patient populations (e.g., illicit drug users) and
other patient subgroups (e.g., patients without human
immunodeficiency virus and treatment-naïve patients)
[9-13].
An additional component of successful treatment for
HCV is the ability to remain motivated throughout the
course of therapy. Several studies have shown that patients
reported challenges in adhering to a PR treatment regi-
men because of side effects, worsening fatigue, and de-
clines in health-related quality of life [10,14]. Decreased
treatment adherence and treatment discontinuation are
associated with a reduced probability of virologic response
[15,16].
The objective of this investigation was to identify factors
reported by HCV-infected individuals in the United States
as important in their decision to start and complete the
prescribed HCV treatment. Study findings should inform
the development of interventions in support of HCV
treatment initiation and maintenance as new treatment
options emerge for this patient population.
Methods
Study procedures were reviewed by New England Institu-
tional Review Board (NEIRB), an independent Institu-
tional Review Board (IRB), and the study was determined
to be exempt from review. All participants were informed
about the study’s purpose and methods. Individuals
provided verbal consent for participation; those who
completed all study related activities received a stipend
of $75.
Study population
Seven hundred and seventy individuals were screened
from a United States community convenience sample, of
whom 123 HCV-infected patients were eligible for the
study and 120 participated. Sources of referral to this
study included support groups for HCV-infected patients
(28%), physician offices (17%), family/friend referrals
(12%), online postings (13%), and other entities (31%),
such as drug treatment centers and shelters.
To qualify for study inclusion, patients must have
reported a diagnosis of HCV infection as well as a positive
diagnostic test. Recruiting criteria did not specify whether
the HCV infection was to be acute or chronic. Currently
treated and previously treated individuals were required to
answer additional questions about their treatment (e.g.,
treatment type and duration) to qualify for the study. Pre-
viously treated patients must have received a course of
treatment within the previous five years.
Potential participants were excluded if they had received
treatment with a DAA. Other exclusion criteria included a
diagnosis of HIV/AIDS, schizophrenia, or major contrain-
dications for treatment (e.g., individuals undergoing can-
cer treatment or with decompensated cirrhosis, liver
failure, liver cancer, or severe cardiac disease). People
employed by a healthcare product manufacturer were ex-
cluded, as were individuals who had received payment for
market research in the prior 30 days.
Pre-recruitment targets were specified with respect to
age groups, gender, race, and treatment experience in an
attempt to ensure adequate representation of the HCV-
infected population in the United States. Table 1 provides
a summary of the pre-recruitment targets for the study
population.
Table 1 Pre-recruitment study sample targets
Patient characteristic Target/soft quota
Gender (male),% ≥ 60
Age (median), years 50
Race/ethnicity,%
Hispanic/Latino 10
American Indian/Alaskan Native 1
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Study design and procedures
A systematic literature review identified key relevant
studies and informed the development of a standardized
interview guide. Between May 2011 and August 2011,
two trained interviewers conducted 60-minute one-on
-one telephone interviews consisting of open‐ and
closed-ended questions about HCV infection and treat-
ment initiation, maintenance, and completion. Inter-
viewers selected one of five differently ordered sets of
closed-ended question (i.e., same questions, different
order) to reduce question order bias; interviewers en-
sured an equal distribution of the five ordered sets. For
Table 2 List of factors potentially affecting HCV treatment decisions*
1 Possible future health problems you expect from not treating Hepatitis C
2 Expected effectiveness of treatment (in terms of the treatment’s typical impact or lack of impact on virus levels)
3 Expected overall side effects of treatment
4 Expected depression side effects in particular
5 Expected flu-like side effects in particular
6 Expected fatigue side effects in particular
7 Amount of time needed to finish the entire treatment
8 The need to inject one of the treatment medications with a needle
9 Having to remember to take several medications according to a schedule from the doctor
10 Possible Hepatitis C treatment alternatives not discussed by your doctor
11 Need for a liver biopsya
12 How Hepatitis C, the disease, has affected (or not affected) other people’s lives
13 How Hepatitis C treatment has affected other people’s lives
14 The stage of your Hepatitis C (for example, your liver status)
15 Whether or not you had Hepatitis C symptoms
16 Other health issues in addition to Hepatitis C, [for women] including pregnancy or possible pregnancy
17 Any substance abuse issues (alcohol or recreational street drugs)
18 The need for more information about Hepatitis C treatments
19 The extent of your will power when you decide to do something (such as starting a treatment)a/ The extent of your will power when you
decide to do something (such as finishing a treatment)b
20 The effect of the condition of Hepatitis C on your ability to reach life goals
21 The effect of the condition of Hepatitis C on the lives of others, such as your family members
22 The effect treatment might have on your ability to meet work responsibilitiesa/ The effect of the treatment on your ability to meet your work
responsibilitiesb
23 The effect treatment might have on your ability to meet family responsibilitiesa/ The effect of the treatment on your ability to meet your family
responsibilitiesb
24 Your ability to pay for treatment
25 The effect treatment might have on your ability to earn moneya/ The effect of treatment on your ability to earn moneyb
26 The stability of your housing situation
27 The emotional support you could expect from friends, family, support groups, and/or religion if you were to start treatmenta/ Emotional support
from your friends, family, support groups, and/or religionb
28 Your doctor’s advice
29 Your relationship with doctors and nurses in terms of the encouragement and knowledge they typically provide
30 Organizational help from doctors and nurses in things like managing appointments and helping with medications
31 How easy or hard it is to see doctors or nurses (for example traveling to the doctor’s office and making appointments)
32 Potential for being treated differently or judged if you were to start treatmenta/ Being treated differently or judged because of the treatmentb
33 Your ability to get information during treatment about your virus levels and how likely the treatment will work for youa/ Information during
treatment about your virus levels and how likely the treatment will work for youb
*Study participants were asked to provide an importance rating for each factor. Naïve patients provided ratings in regards to HCV treatment initiation; unless
otherwise noted, all other patients provided ratings based on the factors’ importance to treatment initiation and completion.
aPatients rated the factor only in regards to importance to HCV treatment initiation.
bPatients rated the factor only in regards to importance to HCV treatment completion.
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the 33 closed‐ended questions about factors that might
influence treatment decisions, participants assigned a rat-
ing from 1 (not at all important) to 5 (extremely import-
ant) and provided verbal explanation of why they
thought each factor was encouraging or discouraging in
initiating and completing HCV treatment (Table 2).
Data analysis
All interviews were recorded and transcribed verbatim
with participant permission. Transcripts were subsequently
coded by one researcher and reviewed by a second re-
searcher to ensure the accuracy of the dataset. Coded re-
sponses were aggregated and summarized for the entire
study population and by participant subgroup. For analytic
purposes, factors described as encouraging by a participant
were assigned a positive importance rating, factors de-
scribed as discouraging were assigned a negative impor-
tance rating, and factors that were neither discouraging
nor encouraging for a participant were assigned a zero
value.
Descriptive statistics were employed to characterize
study findings; analysis of variance (ANOVA) procedures
were used to assess statistical significance in all study
comparisons. Given that treatment motivators may de-
pend on treatment history, patient groups selected for
comparisons are treatment naïve patients, currently
treated patients, patients who have completed treatment,
and patients who have discontinued treatment. Dif-
Table 3 Demographic and clinical characteristics of study participants by treatment* experience
Patient characteristics All (n = 120) Completed (n = 30) Discontinued (n = 30) Current (n = 30) Naïve (n = 30)
Age in years, mean(±SD) 49.1 (±11.6) 56.8 (±8.4) 49.9 (±9.6) 47.6 (±9.7) 42.0 (±13.2)
Male, n (%) 67 (56) 17 (57) 16 (53) 17 (57) 17 (57)
Married, n (%) 29 (24) 11 (37) 8 (27) 7 (23) 3 (10)
Living alone at time of treatment, n (%)a 34 (38) 12 (40) 10 (33) 12 (40) NA
Race/ethnicity, n (%)b
Caucasian/White 76 (63) 25 (83) 16 (53) 22 (73) 13 (43)
African American/Black 28 (23) 3 (10) 8 (27) 6 (20) 11 (37)
Hispanic/Latino 12 (10) 2 (7) 5 (17) 1 (3) 4 (13)
Asian/Native Hawaiian/Other Pacific Islander 3 (3) 0 (0) 1 (3) 1 (3) 1 (3)
American Indian/Alaskan Native 1 (1) 0 (0) 0 (0) 1 (3) 0 (0)
Other 1 (1) 0 (0) 0 (0) 0 (0) 1 (3)
Highest education level, n (%)b
Bachelors/graduate degree 28 (23) 11 (37) 8 (27) 6 (20) 3 (10)
Some college/2 year associate degree 50 (42) 11 (37) 13 (43) 13 (43) 13 (43)
High school diploma/GED 32 (27) 7 (23) 7 (23) 10 (33) 8 (27)
Less than high school 10 (8) 1 (3) 1 (7) 1 (3) 6 (20)
Health insurance status when deciding whether to start treatment , n(%)c
Private 61 (51) 19 (63) 19 (63) 13 (43) 10 (33)
No health insurance 26 (22) 4 (13) 4 (13) 9 (30) 9 (30)
Medicaid only 19 (16) 3 (10) 6 (20) 5 (17) 5 (17)
Medicare or Medicaid/Medicare dual 9 (8) 2 (7) 1 (3) 1 (3) 5 (17)
Military insurance/TRICARE/VA 5 (4) 2 (7) 0 (0) 2 (7) 1 (3)
Comorbid conditions, n (%)d
Depression 62 (52) 10 (33) 16 (53) 19 (63) 17 (57)
Anxiety 53 (44) 9 (30) 11 (37) 15 (50) 18 (60)
Compensated cirrhosis 18 (15) 5 (17) 8 (27) 4 (13) 1 (3)
Diabetes 9 (8) 3 (10) 4 (13) 1 (3) 1 (3)
Time since HCV diagnosis in years, mean (±SD) 7.3 (±5.7) 10.4 (±6.4) 9.1 (±5.0) 5.4 (±5.5) 4.2 (±3.2)
*Treatment refers to pegylated interferon and ribavirin (PR).
aLiving alone at the time of treatment was not assessed for the treatment-naïve population, therefore the total denominator for all patients = 90.
bPercentages may not add to 100% because of rounding.
cCurrent health insurance status (i.e., status at the time of the interview) is captured for treatment-naïve patients.
dPatients may have more than one comorbid condition.
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ferences between groups were considered significant at
p-values ≤0.05.
Results
Patient demographic and clinical characteristics
Participants included 120 adults with HCV infection: 30
treatment naïve, 30 currently treated, and 60 previously
treated - of whom 30 had completed treatment and 30
had discontinued treatment. Fifteen of the patients who
had completed treatment were cured, while 15 had
relapsed or had non-response. Fifty-six percent of the
study participants were male; 63% were white/Caucasian
(Table 3). Median age was 52 years (mean: 49; SD: 11.4),
which was comparable to the median age of the HCV-
infected population in the United States [17]. The geo-
graphic distribution of the study participants was as
follows: West (24%), Northeast (21%), Midwest (18%), and
South (38%). Patients who had completed treatment were
significantly older than other patient subgroups, with
mean age of 57 years (SD: 8.4; p < 0.001) compared with
mean age of 42 years (SD: 13.2) in the treatment naïve
group, 48 years (SD: 9.7) in the currently treated group,
and 50 years (SD: 9.6) in the group who had discontinued
treatment. In addition, duration of disease was longer for
patients who had completed treatment (10.4 years; SD:
6.4; p < 0.001) than for other groups: naïve (4.2 years; SD:
3.2), current (5.4 years; SD: 5.5), and discontinued
(9.1 years; SD: 5.0).
Factors encouraging and discouraging patients to initiate
treatment
The five factors reported as most encouraging for treat-
ment initiation (followed by the mean importance scores)
were possible future health problems from not treating
HCV infection (4.8), participant’s willpower (4.1), doctor’s
advice (4.1), the impact that HCV had or might have on
reaching life goals (3.6), and the ability to obtain informa-
tion during treatment on the likelihood of treatment suc-
cess (3.5). The most discouraging factors were: the overall
side effects of treatment (−3.0), fatigue (−2.9), flu-like
symptoms (−2.6), depression (−2.4), and the need to inject
one of the treatment medications (−2.0) (Figures 1 and 2).
Possible future health problems associated with HCV
infection
All four patient subgroups assigned similar importance
ratings and indicated similar concerns with disease pro-
gression when considering the initiation of HCV treat-
ment (p = 0.542). Fears of progressing towards cirrhosis,
liver failure, liver cancer, and death were commonly
mentioned. Comments from two currently treated pa-
tients are below.
Current: “[Possible future health problems] was the
most important aspect in my mind at that point. I did
not want to end up to be an invalid or an extremely
sickly person for the rest of my life because I didn’t or
wasn’t willing to try an approach to hopefully fight
and heal a disease, or at least bring something that’s
out of balance more in balance.”
Current: “I didn‘t want to die of liver cancer or
cirrhosis.”
Among naïve patients, however, concern about future
health problems associated with HCV infection was
Figure 1 Most important factors encouraging and discouraging the initiation of HCV treatment (n = 120).
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often not enough of a concern to seek treatment imme-
diately. Other issues, such as expected medication side
effects (cited by 60% of naïve patients), physician recom-
mendations (40%), and disease stage (40%), were reported
to have influenced their decisions to decline treatment as
well.
Participants’ willpower
All four study subgroups reported similar ratings for the
importance of inner strength/willpower as motivation to
start HCV therapy (p = 0.938).
Current: “I mean once you commit yourself that’s it.
I’m not a middle of the road guy. It’s either 100% or
don’t do it at all.”
As shown in the comment below, some patients who
recognized their lack of willpower stressed the import-
ance of finding strength from other sources.
Completed: “My willpower has never been very good.
That’s why I got support. They help you with your
willpower. Willpower—it’s important. We got to have
the will to do it, but the support group helps you get
that will better lined up.”
Doctor’s advice
Study participants generally valued the opinion of their
clinicians and recognized their expertise as important for
guiding them through the treatment decision process. Pa-
tients reported doctor’s advice to be important in encour-
aging their decision to initiate treatment; no differences
were observed between subgroups (p = 0.294). Specifically,
patients mentioned that they valued their clinician’s train-
ing, experience, and knowledge. Patients also reported
that they were further encouraged by their clinician’s
positive feedback and confidence regarding treatment
effectiveness and associated outcomes. Forty percent
of naïve patients indicated that they had deferred
HCV treatment initiation because of their clinician’s
recommendation.
Discontinued: “I have no medical training or skills. I
have to rely on what my doctor suggests or what he
recommends in order to make a decision as to what
I’m going to do.”
The patients quoted below noted that their doctors
had provided information that allowed them to make
treatment decision themselves.
Completed: “The doctor pretty much left it up to me.
He didn‘t advise me to go for it or not to go for it. It
was not a question of live or die thing because I was at
such a low stage.”
Completed: “[The doctors] left it [the treatment
decision] up to me. They didn‘t force it on me. It was
if I made the decision I would probably be more likely
to go through it, than if they made the decision.”
Despite overall clinician praise, the comments below
show some disappointment in clinicians’ advice regard-
ing treatment.
Completed: “I sometimes wish that he were a little
more aggressive, a little less conservative in treating
this virus.”
Current: “I am really not sure how much he knew
about this disease.”
Current: “He didn't seem to care. Like I said, in the
beginning all he said was, ‘We can give you a shot.’”
Figure 2 Most important factors encouraging the initiation of HCV treatment by subgroup. ** The treatment mentioned in subgroup
descriptions refers to treatment with pegylated interferon and ribavirin (PR). **Difference between groups is statistically significant at p≤ 0.05.
Sample sizes may vary for individual factors because of missed questions or participant non-response.
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Impact of HCV infection on ability to reach life goals
Across all patient subgroups, the impact of HCV infection
on patients’ ability to reach life goals was important to the
treatment decision. Goals reported as unattainable with
HCV infection included living a happy, healthy, and long
life, pursuing and advancing in a career, furthering educa-
tion, participating in recreational activities (e.g., travel and
sports), and starting a family or spending time with
existing family. Patients who had previously completed
treatment, assigned slightly lower importance to this fac-
tor; differences in the mean importance rating were not
statistically significant between subgroups (p = 0.638).
Naïve: “I want to be there for my kids, live to see
them grow up. I have a relative who is dying of
hepatitis C.”
Naïve: “If I get sick because I have hep C and I can’t
physically work, it’s going to affect all kinds of things.
It’s going to affect my income. It’s going to affect my
job. It’s going to affect my home life.”
Ability to get information on the likelihood of treatment
success
Sixty-nine percent of all participants (77% [naïve ]; 67%
[currently or previously treated]) indicated that the ability
to know the likelihood of treatment success would en-
courage them to initiate treatment. The naïve group
assigned a greater importance rating to the ability to ob-
tain this information compared with all other participant
groups (p = 0.005).
Of the 69% of participants who reported that this infor-
mation would encourage them to start treatment, 29%
indicated that they would like to know (or would have
liked to have known) these results within four weeks of
treatment initiation. An additional 16% of participants
motivated by this information indicated that they would
prefer this information “as soon as possible.” The median
preferred timing for viral load results was reported to be
five weeks across all study participants reporting to be
motivated by this type of information (Figure 3). For
naïve participants, the reported timing preferred for viral
load results was later (median: 10 weeks).
Study participants were generally interested in under-
standing the effectiveness of therapy during the course
of treatment. Some patients specifically indicated that
having the opportunity to review these results afforded
them some level of control over their treatment.
Current: “I want to make sure that if I’m going to
undergo something, it’s going to work. I just don’t want
to waste my time with something.”
Discontinued: “Just knowing what’s going on, for me, is
very, very important. I don’t like to be in the dark, and
I like to be able to make decisions or just know what’s
going on.”
Side effects of HCV treatment
The four most important factors that discouraged treat-
ment initiation among study participants were related to
overall and individual treatment side effects such as fa-
tigue, flu-like symptoms, and depression. Forty percent of
all study participants anticipated fatigue, 40% anticipated
flu-like symptoms, and 25% anticipated depression; how-
ever, the potential for other side effects was of concern.
Naïve: “I hear horrible stories on the internet.”
Naïve: “I had seen somebody on it and they were very
sick and very weak and tired. Then if you do
something with it and you drink or something like
that, you know, you could get even worse. Then you
like start throwing up and get all depressed and all
that, so I’m scared to take it.”
Figure 3 Preferred timing for data about likelihood of treatment success for participants motivated by this factor (n = 61*). *An
additional 13 patients mentioned “as soon as possible” and four mentioned “early on during treatment.”
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Current: “My thoughts were am I going to be able to
keep up with all of this. Am I going to have the energy?
Am I going to be well enough to keep doing what I'm
doing?”
The importance assigned to side effects was higher for
the naïve and current subgroups than for the previously
treated subgroup (p = 0.004). In the naïve participant
group, 60% of participants indicated that treatment-
related side effects were a primary reason for not initiating
treatment.
Need to inject one of the treatment medications
The method of treatment administration also factored into
patients’ treatment decisions, with similar importance rat-
ings across the four subgroups (p = 0.507). Fear of needles,
discomfort with self-injections, and reminders of illicit
drug use were cited as issues that discouraged treatment
initiation, as seen in the quotations below.
Completed: “I don't like shots and I certainly didn’t
want to have to give myself one.”
Naïve: “I don't like needles because of my IV drug
history. It's a trigger for me.”
Previously treated patients offered some suggestions for
facilitating treatment injections. Eleven percent of previ-
ously treated participants specifically highlighted the im-
portance of training materials and guidance from their
clinicians with respect to injection sites, general tech-
nique, and numbing or distraction strategies. Ten percent
of previously treated patients suggested having someone
else administer the medications.
Factors encouraging and discouraging patients to
complete treatment
The top five factors reported as encouraging for the
adherence to and completion of treatment were the fol-
lowing (Figures 4 and 5): possible future health problems
from not treating HCV infection, patients’ willpower,
stage of disease, available emotional support, and doctor’s
advice. Although the stage of HCV disease and the avail-
ability of emotional support from others (e.g., friends,
family, support groups) were not in the top five factors
encouraging treatment initiation, they became more im-
portant in decisions to complete treatment. We provide
more detail on these two factors in the sections below;
we do not provide further detail on the other three fac-
tors because patients’ comments were almost identical to
the comments provided in the section on treatment
initiation.
The two most important factors discouraging HCV
treatment adherence or completion were treatment-re-
lated side effects and overall treatment duration.
Stage of HCV disease
In particular, study participants who were currently
treated or had discontinued treatment reported that the
stage of their liver disease was an important factor for ad-
hering to the prescribed HCV regimen and for completing
treatment. As their disease had progressed, so did their
desire to complete HCV therapy.
Figure 4 Most important factors encouraging and discouraging HCV treatment completion.
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Completed: “I was really wanting to get rid of it, so it
wouldn‘t do any worse damage.”
Availability of support
Previously treated patients (i.e., patients who had finished
or discontinued treatment) and currently treated patients
reported that support from family, peers, and health care
providers encouraged treatment adherence and comple-
tion, as did religious faith.
Current: “I think definitely anybody going into it
should go to a support group and talk to people that
have been through it. That’ll definitely help you. It
really raises your hopes when you see people that it
has worked with, and they can tell you about their
experience, what they went through with it, and how
their lives are changed after going through it.”
Discontinued: “Just moral support from friends and
family and reading online forums of people's suggestions,
like doing the injection at night time so you sleep
through the initial worse side effects. Just try to be
informed and take other peoples’ suggestions to heart.”
Side effects of HCV treatment
On a scale of 1 (not at all bothersome) and 5 (extremely
bothersome), the mean rating of treatment side effects for
the previously and currently treated participants combined
was −3.69 (−3.38 [current], -3.90 [discontinued], and −3.78
[completed], respectively) (These differences were not sig-
nificant.) Side effects were more bothersome for patients
who had discontinued treatment than for other subgroups,
and 43% of patients who had discontinued mentioned side
effects as a reason for stopping HCV treatment.
Survey participants offered several suggestions for strat-
egies to overcome treatment side effects. The use of
additional medications (e.g., anti-nausea drugs, antidepres-
sants, over-the-counter flu medications) was reported as
helpful, as were exercise, rest, positive thinking, and distrac-
tion. In addition, an important strategy was to take medica-
tions as part of a daily routine (i.e., before bed and
injections over weekends) to avoid interference with pa-
tients’ usual activities and a work day.
Current: “Trying to ignore them—like focus on
something else—actually, do something—not just lay
around feeling miserable.”
Current: “I do a meditation class with my
acupuncturist, and acupuncture has helped through
the treatment. It helped a lot for my anxiety and my
moods, my nausea, and so many of the side effects.”
Discontinued: “Sometimes I’d just wait until Saturday—
a better day, the weekend. Who cares? I don’t have to
work. Do them then and then it didn’t affect me so
much—the side effects.”
Treatment duration
Doubts about being able to complete treatment were
reported to have emerged during treatment; such doubts
were tied both to the administration of medication and
the medications’ side effects. As seen in the comment
below, participants indicated that they would have been
more willing to endure the side effects if they had
known that treatment could be shorter.
Discontinued: “If I were to have to go 12 months with
these types of feelings I wouldn‘t be able to do it. But
Figure 5 Most important factors encouraging HCV treatment completion by subgroup. ** The treatment mentioned in subgroup
descriptions refers to treatment with pegylated interferon and ribavirin (PR). **Difference between groups is statistically significant at p≤ 0.05.
Sample sizes may vary for individual factors because of missed questions or participant non-response.
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on the other hand if I had to go two more months I
would have probably stayed with it.”
Discussion
Study findings suggest that future health problems re-
lated to chronic HCV infection and the expected efficacy
and safety profile of HCV therapies are likely to impact
patients’ decisions on HCV treatment initiation and
completion. Such risk-benefit considerations have been
reported to be more likely to increase patient satisfaction
than other decision paradigms [8] and to provide a
promising foundation for those seeking to increase HCV
treatment adherence and completion [18].
The expectation of health problems from not treating
HCV infection was identified as the most important fac-
tor for encouraging therapy initiation, consistent with
data from an Australian study [10]. Patients want to be
in good health now and in the future but while HCV
treatment may provide future health benefits, side effects
make patients feel poorly in the present. Participants in
our research indicated that side effects of treatment were
most important both in discouraging treatment start and
in challenging treatment adherence.
Early knowledge of the likelihood of treatment success
was suggested to be of great value to many patients.
Based on the study findings, the ability to obtain labora-
tory testing results in the early treatment phase could be
a motivating factor for patients to seek HCV treatment
and to adhere to therapy following their decision to initi-
ate therapy. Our study findings could be relevant to those
patients initiating the newer therapies available including
DAA-based regimens. In such instances, guidelines is-
sued by the American Association for the Study of Liver
Diseases (AASLD) for the treatment of genotype 1
chronic HCV infection [6] should be consulted in deter-
mining the value of early on-treatment viral load
assessments.
Analyses of the factors that are important to patient
treatment decisions (e.g., expectation of future disease
complications and treatment side effects), coupled with
earlier research indicating that physicians may not
understand how patients value the risks and benefits of
antiviral therapy [19], suggest the utility of informing cli-
nicians of the patient perspective regarding HCV treat-
ment. In our research, patient suggestions on how to
overcome barriers to starting HCV treatment included
keeping communication open between the patient and
doctors, nurses, and pharmacists. Communication and
education are especially helpful given the importance of
physician recommendations in patient decisions about
whether or not to begin HCV therapy [8].
It is also important for clinicians to understand nuances
in patients’ decision-making processes for those with and
without prior HCV treatment experience. For example,
side effects were more discouraging in treatment-naïve
than in treatment-experienced patients, whereas the abil-
ity to get information on the chance of treatment success
was identified as a higher motivating factor in treatment-
naïve patients. Fear of potential side effects may subside
somewhat once patients have experience with the treat-
ment regimen whereas the ability to learn about the likeli-
hood of treatment success early during treatment may
resonate highly in treatment-naïve patients.
Our results suggest the need for clinicians to educate
patients in the areas of disease progression, the potential
of long-term clinical consequences if treatment is post-
poned, and the challenges of treatment-related side ef-
fects. Based on our research, discussion topics should
also include education about treatment duration, as well
as the importance of committing to treatment in light of
the consequences of early treatment discontinuation.
Clinician support would also include training in medica-
tion administration and management of side effects.
Other research has shown that similar education pro-
grams in HCV-infected patients eased their fears and in-
creased rates of treatment eligibility [20].
This study, along with others [21-23], highlights the im-
portance of emotional support (family, friends, and sup-
port groups), peer-to-peer conversations, and support
groups for HCV-infected patients. Many patients have
reported to find support groups more useful than pro-
viders at providing health-related information [22]. In our
research, patients repeatedly suggested the value of identi-
fying individuals in comparable circumstances as a way to
encourage treatment initiation. Peer education and sup-
port groups can help patients understand how others have
successfully managed their disease and treatment; emo-
tional support may also be provided by bringing together
patients at similar stages of treatment.
Several limitations should be considered when evaluat-
ing study findings. First, with the exception of the rating
exercises, the research methodology was qualitative. Such
methods, however, provide an opportunity to gain a
deeper understanding of the individual decision-making
process in regards to HCV treatment initiation and com-
pletion. Second, although the importance ratings of some
factors are significantly different across patient groups,
the sample sizes of the patient groups may have been too
small to detect statistically significant differences for
other important factors. Third, true motivators may be
different than reported motivators, especially for previ-
ously treated patients tasked with recalling the factors
that had motivated them in the past. This is an inherent
limitation of this study design. Fourth, this study
employed a convenience sample, which has the potential
to impact the generalizability of the results. To help
counteract this potential limitation, we employed quotas
for key patient characteristics reflecting the distribution
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of such factors in the HCV-infected population in the
United States. Lastly, because the design of this study did
not allow for access to medical records, we were unable
to verify conclusively that all survey participants had a
diagnosis of HCV infection; however, patients who
reported being currently or previously treated had to an-
swer additional questions about treatment type and dur-
ation to qualify for study inclusion.
Conclusion
HCV-infected individuals often choose to defer initiating
treatment or to discontinue therapy. Understanding po-
tential motivators and treatment challenges from the
patient perspective is an important means to identify op-
portunities for education and interventions that encourage
initiation and completion of HCV treatment.
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